At the time of the final analysis for progression-free survival ( median follow-up @ months -LSB- @ % CI @-@ @ -RSB- for the palbociclib plus letrozole group and @ months -LSB- @-@ @ -RSB- for the letrozole group ) , @ progression-free survival events had occurred in the palbociclib plus letrozole group and @ in the letrozole group .